Evidence map›Paper›PMID 33764312›Full record

ArticleThe Journal of endocrinology2021

Lower threshold to NFκB activity sensitizes murine β-cells to streptozotocin.

Clyde J Wright, Sarah McKenna, Robyn De Dios, Brit H Boehmer, Leanna Nguyen, Sankar Ghosh, Jeryl Sandoval, Paul J Rozance

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Role of ceramides in diabetic foot ulcers (Review).International journal of molecular medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Clyde J WrightSection of Neonatology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Sarah McKennaSection of Neonatology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Robyn De DiosSection of Neonatology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Brit H BoehmerSection of Neonatology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Leanna NguyenSection of Neonatology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Sankar GhoshDepartment of Microbiology and Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Jeryl SandovalSection of Neonatology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Paul J RozanceSection of Neonatology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
University of Colorado Denver · USColumbia University · US

Funding

University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8M
Training Program in Perinatal Biology and MedicineT32HD007186 · NICHD · UNIVERSITY OF COLORADO DENVER · PI Paul Joseph Rozance · 1985 to 2026
$6.5M
Nutrient Coordination of Pancreatic Vasculature and Beta-CellsR01DK088139 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI ROZANCE, PAUL JOSEPH · 2011 to 2020
$5.1M
Physiological Ramifications of Chorionic Somatomammotropin DeficiencyR01HD093701 · NICHD · UNIVERSITY OF COLORADO DENVER · PI ANTHONY, RUSSELL V, ROZANCE, PAUL JOSEPH · 2018 to 2022
$2.9M
Role of hepatic IkBb-mediated sustained NFkB activation in neonatal lung injury and abnormal developmentR01HL132941 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI WRIGHT, CLYDE JASON · 2017 to 2021
$2.3M
Understanding the importance of IkB-b as a selective co-activator of NF-kB signalingR01AI139217 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GHOSH, SANKAR · 2018 to 2022
$2.0M
NHLBI NIH HHS R01 HL132941NIAID NIH HHS R01 AI139217NICHD NIH HHS R01 HD093701NICHD NIH HHS T32 HD007186NIDDK NIH HHS P30 DK116073NIDDK NIH HHS R01 DK088139
6 · The paper itself

Abstract

The β-cell response to injury may be as critical for the development of diabetes as the specific insult. In the current study, we used streptozotocin (STZ) to injure the β-cell in order to study the response with a focus on NFκB. MIN6 cells were exposed to STZ (0.5-8 mM, 0-24h) ±TNFα (100 ng/mL) and ±IκBβ siRNA to lower the threshold to NFκB activation. Cell viability was determined by trypan blue exclusion. NFκB activation was determined by the expression of the target genes Nos2 and Cxcl10, localization of the NFκB proteins p65 and p50, and expression and localization of the NFκB inhibitors, IκBβ and IκBα. There was no NFκB activation in MIN6 cell exposed to STZ (2 mM) alone. However, knocking down IκBβ expression using siRNA resulted in STZ-induced expression of NFκB target genes and increased cell death, while co-incubation with STZ and TNFα enhanced cell death compared to either exposure alone. Adult male IκBβ-/- and WT mice were exposed to STZ and monitored for diabetes. The IκBβ-/- mice developed hyperglycemia and diabetes more frequently than controls following STZ exposure. Based on these results we conclude that STZ exposure alone does not induce NFκB activity. However, lowering the threshold to NFκB activation by co-incubation with TNFα or lowering IκBβ levels by siRNA sensitizes the NFκB response to STZ and results in a higher likelihood of developing diabetes in vivo. Therefore, increasing the threshold to NFκB activation through stabilizing NFκB inhibitory proteins may prevent β-cell injury and the development of diabetes.

Indexed as

AnimalsCell Line, TumorCell SurvivalChemokine CXCL10Diabetes Mellitus, ExperimentalGene Expression RegulationGene SilencingI-kappa B KinaseInsulinomaInsulin-Secreting CellsMaleMiceMice, KnockoutNF-kappa BNitric Oxide Synthase Type IIStreptozocinChemokine CXCL10Cxcl10 protein, mouseI-kappa B KinaseNF-kappa BNitric Oxide Synthase Type IINos2 protein, mouseStreptozocinTumor Necrosis Factor-alphaCxcl10diabetesIκBNFκBNos2Streptozotocinβ-cell

Identifiers

PMID33764312
PMCPMC8113150
OpenAlexW3139098274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.